Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taroh Satoh

Showing results (81-90 of 277) with videos related to

Pageof 28
Sort By:
Molecular Cancer Therapeutics|March 19, 2008
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthaseTakafumi Okabe, Isamu Okamoto, Sayaka Tsukioka, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 31, 2017
[Recurrence of Jejunal Carcinoma in the Ileum and Ovary - A Case Report]Nobuyoshi Ohara, Naotsugu Haraguchi, Toshihiro Kudo, et al.
Cancer Chemotherapy and Pharmacology|June 25, 2016
Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancerTsuyoshi Hata, Toshihiro Kudo, Daisuke Sakai, et al.
Ebiomedicine|July 3, 2015
Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter StudyTakayuki Yoshino, Kei Muro, Kensei Yamaguchi, et al.
Anticancer Research|August 28, 2025
Efficacy and Safety of S-1 and Oxaliplatin With Radiotherapy for Anorectal CancerNoriko Wada, Naohiro Nishida, Mitsunobu Takeda, et al.
Investigational New Drugs|September 18, 2009
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancerIsamu Okamoto, Masaki Miyazaki, Ryotaro Morinaga, et al.
Cancer Chemotherapy and Pharmacology|August 20, 2011
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancerTaroh Satoh, Yasuhide Yamada, Kei Muro, et al.
Esophagus : Official Journal of the Japan Esophageal Society|June 20, 2022
A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404)Motoo Nomura, Takayuki Kii, Junji Kawada, et al.
Esophagus : Official Journal of the Japan Esophageal Society|January 19, 2024
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302Hiroki Hara, Taroh Satoh, Takashi Kojima, et al.
BMC Cancer|July 23, 2022
Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II studyShunji Endo, Tetsuji Terazawa, Masahiro Goto, et al.
Pageof 28

Showing results (81-90 of 277) with videos related to

Sort By:
Pageof 28
Molecular Cancer Therapeutics|March 19, 2008
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthaseTakafumi Okabe, Isamu Okamoto, Sayaka Tsukioka, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 31, 2017
[Recurrence of Jejunal Carcinoma in the Ileum and Ovary - A Case Report]Nobuyoshi Ohara, Naotsugu Haraguchi, Toshihiro Kudo, et al.
Cancer Chemotherapy and Pharmacology|June 25, 2016
Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancerTsuyoshi Hata, Toshihiro Kudo, Daisuke Sakai, et al.
Ebiomedicine|July 3, 2015
Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter StudyTakayuki Yoshino, Kei Muro, Kensei Yamaguchi, et al.
Anticancer Research|August 28, 2025
Efficacy and Safety of S-1 and Oxaliplatin With Radiotherapy for Anorectal CancerNoriko Wada, Naohiro Nishida, Mitsunobu Takeda, et al.
Investigational New Drugs|September 18, 2009
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancerIsamu Okamoto, Masaki Miyazaki, Ryotaro Morinaga, et al.
Cancer Chemotherapy and Pharmacology|August 20, 2011
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancerTaroh Satoh, Yasuhide Yamada, Kei Muro, et al.
Esophagus : Official Journal of the Japan Esophageal Society|June 20, 2022
A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404)Motoo Nomura, Takayuki Kii, Junji Kawada, et al.
Esophagus : Official Journal of the Japan Esophageal Society|January 19, 2024
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302Hiroki Hara, Taroh Satoh, Takashi Kojima, et al.
BMC Cancer|July 23, 2022
Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II studyShunji Endo, Tetsuji Terazawa, Masahiro Goto, et al.
Pageof 28